Syncona

Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Clade Therapeutics is a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem-cell-based medicines. The company was incorporated in 2020 and has been operating in Cambridge, Massachusetts, United States.

Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Purespring Therapeutics is a pioneering company focused on developing gene therapies for various kidney diseases, particularly targeting podocytes, which are specialized kidney cells. The company is among the first globally to employ AAV gene therapy specifically for kidney conditions, aiming to tackle one of the most challenging areas in medicine.

SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders.

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.

Azeria Therapeutics is a developer of a cancer drug intended to aid in the treatment of breast and prostate cancer patients. The company develops a pipeline of small molecules designed to selectively inhibit pioneer factors, enabling medical professionals to treat cancer patients.

NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.

Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing or dysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products.

Blue Earth Diagnostics to develop and commercialise molecular imaging agents addressing areas of high un-met medical need. The company is named after Blue Earth County, Minnesota where Sir Henry Wellcome (1853-1936), the founder of the Wellcome Trust, spent his childhood. Wellcome was one of the most fascinating men of his time. A businessman, collector and philanthropist, he was born in the American Wild West but ended his days as a knight of the British Realm. He co-founded a multinational pharmaceutical company that mastered modern techniques of advertising such as promotion, image and branding. He also funded pioneering medical research, in his lifetime, scientists funded by Wellcome made great breakthroughs into understanding how our bodies work. After his death the great man’s will provided for the creation of the Wellcome Trust, whose venture investment arm Syncona Partners LLP (“Syncona”) are the founding investors in BED.

Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.

NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.